Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development

1. Front Matter

   Pages i-xvii

   PDF

2. Drug Discovery — 1990

   • Frederick Valeriote, Thomas Corbett, Laurence Baker

   Pages 1-9

3. Data Display and Analysis Strategies for the NCI Disease-Oriented in Vitro Antitumor Drug Screen

   • M. R. Boyd, K. D. Paull, L. R. Rubinstein

   Pages 11-34

4. Discovery of Solid Tumor Active Agents Using a Soft-Agar-Colony-Formation Disk-Diffusion-Assay

   • Thomas H. Corbett, Frederick A. Valeriote, Lisa Polin, Chiab Panchapor, Susan Pugh, Kathryn White et al.

   Pages 35-87

5. Thymidylate Synthase Inhibition of Modified Quinazoline Antifolates

   • A. J. Barker, L. R. Hughes, P. Warner, K. Burrows, A. L. Jackman

   Pages 89-103

6. DNA-Minor Groove Binding Anticancer Agents

   • Wendell Wierenga

   Pages 105-122

7. 2-((Arylmethyl)Amino)-1, 3-Propanediols (AMAPS); Discovery, Selection and Development of Four Clinical Candidates

   • Kenneth W. Bair

   Pages 123-147

8. Mechanism-Based Approaches to Cancer Drug Discovery

   • Paul H. Fischer, Eric R. Larson, Robert L. Dow, Penny E. Miller

   Pages 149-157

9. Discovery and Bulk Production of Natural Products with Anticancer Activity: The Role of Chemical Ecology

   • Matthew Suffness

   Pages 159-177

10. Chemical Approaches to Improved Radiotherapy

    • W. R. Leopold, Judith S. Sebolt-Leopold

    Pages 179-196

11. Large Scale Anticancer Drug Screening at Sterling Drug Inc.

    • Paul F. Cavanaugh Jr., Kenneth C. Mattes

    Pages 197-204

12. Are Antisense Oligonucleotides Therapeutic Agents of the Future?

    • George S. Johnson

    Pages 205-214

13. Supercomputer Aided Drug Design: Application in Oncology and AIDS

    • Frederick H. Hausheer, U. Chandra Singh, Jeffrey D. Saxe, Alexander L. Weis

    Pages 215-224

14. Extrachromosomal DNA as a Target for Drug Development

    • Daniel D. Von Hoff

    Pages 225-236

15. Prospective Evaluation of a Predictive Model for Plasma Concentration-Versus-Time Profiles of Investigational Anticancer Drugs in Patients

    • David S. Alberts, Denise J. Roe, Patricia M. Plezia, John G. Kuhn, Lisa E. Davis

    Pages 237-245

16. Agent-Directed Preclinical Toxicology for New Antinfoplastic Drugs

    • Charles K. Grieshaber

    Pages 247-259

17. Preclinical Studies with Brequinar Sodium: A Novel Anticancer Agent

    • Shih-Fong Chen, Daniel L. Dexter

    Pages 261-280

18. Diphtheria Toxin-Related Peptide Hormone Fusion Proteins: New Toxins with Therapeutic Potential

    • John R. Murphy, Diane P. Williams, Tetsuyuki Kiyokawa, Paige L. Anderson, Terry B. Strom

    Pages 281-301

19. Anti-Growth Factor Receptor Antibodies as Therapy for Cancer

    • Raymond Taetle

    Pages 303-323

20. Regulation of Polyamine Biosynthetic Activity and Homeostasis as a Novel Antiproliferative Strategy

    • Carl W. Porter, Debora L. Kramer, Ralph J. Bernacki, Raymond J. Bergeron

    Pages 325-344

The focus of the 22nd Annual Detroit Cancer Symposium was the presentation and discussion of cytotoxic agents, with a significant portion of the symposium including the exciting frontiers of drug discovery being explored by the National Cooperative Drug Discovery Groups (NCDDG) Program. The symposium brought together a large number of investigators from government, universities and pharmaceutical companies involved in the discovery and development of new anticancer agents. Exciting new leads were presented and the status of others presently under development was discussed.
Of particular significance has been the initiation of renewed efforts in the area of natural product drug discovery, where the discovery of new cytotoxics is very promising at the moment. A number of major changes have occurred during the last decade in research on drug discovery of cytotoxic agents. Critical reviews of a number of the models and concepts underlying drug discovery represented a continuous thread throughout the meeting, being constantly discussed in terms of their advantages, disadvantages and capabilities of discovering solid tumor active anticancer agents.
A recent development which is to be much applauded and which portends to great discoveries is the new relationship formed between Government, University of Industry. The NCDDG mechanism which stimulates this interaction is an inexpensive manner to greatly magnify the drug discovery and development effort nationally. Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development represents a forum which will become the major mode for bringing together these three different components in the equation to regularly discuss new results and ideas.

• AIDS
• DNA
• drug design
• hormones
• radiotherapy
• screening
• tumor

• Wayne State University School of Medicine, Detroit, USA

  Frederick A. Valeriote, Thomas H. Corbett, Laurence H. Baker

Policies and ethics